We are an alpha-particle radiopharmaceutical company dedicated to developing a new class of personalized alpha-particle Theranostics
Viewpoint Molecular Targeting is a radiopharmaceutical company developing precision oncology therapeutics and complementary diagnostic imaging agents. The Company’s leading 212Pb-based alpha-particle radiotherapies are designed to deliver powerful alpha radiation specifically to cancer cells utilizing specialized targeting peptides. Viewpoint is also developing complementary imaging diagnostics that utilize the same targeting peptide, which provides the opportunity to personalize treatment using quantitative imaging information. This “theranostic” approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity associated with many other types of cancer treatments.
The Company’s melanoma (VMT01) and neuroendocrine tumor (VMT-𝛼-NET) programs are entering Phase 1 imaging studies, to be followed by Phase 1/2a therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at two leading academic institutions.
Viewpoint Molecular Targeting is devoted to the rapid development of
targeted alpha-particle radiotherapies with the power to cure cancer patients.
To be the global leader in the development and delivery of life-saving
targeted alpha-particle radiotherapies for cancer.